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Abstract
Cancer is a leading cause of mortality worldwide, accounting for 8.8 million 
deaths in 2015. The landscape of cancer therapeutics is rapidly advancing with 
development of new and sophisticated approaches to diagnostic testing. Treatment 
plan for early diagnosed patients include radiation therapy, tumor ablation, surgery, 
immunotherapy and chemotherapy. However the treatment can only be initi-
ated when the cancer has been diagnosed thoroughly. Theranostics is a term that 
combines diagnostics with therapeutics. It embraces multiple techniques to arrive 
at comprehensive diagnosis, molecular images and an individualized treatment 
regimen. Recently, there is an effort to tangle the emerging approach with nano-
technologies, in an attempt to develop theranostic nanoplatforms and methodolo-
gies. Theranostic approach to management of cancer offers numerous advantages. 
They are designed to monitor cancer treatment in real time. A wide variety of 
theranostic nanoplatforms that are based on diverse nanostructures like magnetic 
nanoparticles, carbon nanotubes, gold nanomaterials, polymeric nanoparticles and 
silica nanoparticles showed great potential as cancer theranostics. Nano therapeu-
tic platforms have been successful in integrating image guidance with targeted 
approach to treat cancer.
Keywords: nanomedicine, theranostics, targeted delivery, cancer, functionalized 
nanomedicine
1. Introduction
Cancer has a major impact on society across the world. Estimated number of 
new cases of cancer, current cases of cancer, deaths, survival rate, mortality and in 
depth information, symptoms of cancer, its early detection, prevention and treat-
ment all are provided by American Cancer Society. Nearly 13% of cancer diagnosed 
in 2017 was in the young at age of 20. The new review statistics shows 28 types of 
rare cancer which talks about mortality rate, survival, diagnosis and also provides 
an idea about symptoms and risk factors related to different types of cancer [1].
Therapeutic approaches such as development of nanoemulsions, liposomes, 
microspheres and nanoparticles have facilitated in fighting cancer. Among these, 
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the simplest platforms are the nanoemulsion having size range of 100 to 500 nm 
which are kinetically stabilized having high content of oil and low amount of 
surfactant [2]. Solubility of poorly soluble drugs [3, 4] and its bioavailability can be 
increased by converting the drug into forms like capsule and gels [5] or can be used 
in their original form. The method used for the fabrication of nanoemulsion are 
high energy methods (microfluidization and sonication) and low energy emulsifi-
cation method [6–8].
Theranostics is a term originally coined to define an approach that combine’s 
diagnostics with therapeutics [9]. It embraces multiple techniques to arrive at 
comprehensive diagnosis, molecular images and an individualized treatment 
regimen [10, 11]. Recently, there is an effort to tangle the emerging approach with 
nanotechnologies, in an attempt to develop theranostic nanoplatforms and meth-
odologies [12]. Given that cancer is a highly heterogeneous and adaptable disease, 
diverse types of treatment options need to be chosen depending on patient’s 
characteristics and disease progression.
2. Theranostics
Drugs or methods that are used for accompanying diagnosis and cure [13] are 
referred to as Theranostics. One of the achievements of nanotechnology is the 
fabrication of theranostic nanomedicine for the preparation of these types of drugs. 
The term defines “a nanotherapeutic system which can deliver targeted therapy and 
diagnose”. This aspect provides help when fabricating nano based image contrasting 
agent and also in image guided therapeutics [14].
Rapid drug development, advanced disease management, reduced associated 
risk and cost are assumed to be the result of mutual techniques. Such type of inves-
tigation which involves quick diagnosis and treatment are very helpful in disease 
which are a major cause of morbidity and/or mortality and cancer is one of the 
disease and coincidently the initial research in theranostic is dedicated to oncology. 
Sound knowledge, core understanding of detection and therapy mechanism are 
required for the formation of theranostic agents. In order to fabricate theranostic 
agents one should have understanding of diagnostic strategies, molecular mecha-
nism adverse effect and toxicity of material and techniques for nanoparticles 
preparation for therapy and diagnostic purpose.
Research in theranostics has rapidly improved in the past decade resulting into 
preparation of different contrast media and active ingredient with different method 
of preparation. Preparation of dual purpose nanoparticle system is the main aim 
of theranostics. Therefore it is important to put attention on all factors that influ-
ences the process, right from the preparation of nanoemulsion/nanoparticle till the 
removal of metabolites of the active molecules and other materials used. The factors 
can be the compatibility between chemicals, the condition in which the formulation 
is prepared, modification in formulations because of selected route of administra-
tion, the toxicity, metabolites of active ingredient, its biocompatibility and biode-
gradability and evaluation of pharmacodynamic and pharmacokinetic parameter 
and eventually the disadvantage and benefits of the process.
The basis of diagnosis in theranostics depends upon using different contrast 
agent during imaging. MRI is the most studied and used technique among all 
different imaging mechanism and a lot has been spent on research related to 
magnetic particles used as contrasting agent. Metals like gold, silver, iron oxide 
have been studied with the object of finding suitable particle for imaging with 
least toxicological effect. Diseased tissue and healthy tissue are differentiated in 
MRI by the use of these particles.
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As stated one of the brutal disease is cancer and hence theranostic research has 
put an eye on this area. Day by day the research is going on in positive direction and 
much useful research has already been carried out. In order to understand the con-
cept of diagnosis of cancer and therapy related to it the use of nanoparticle agents 
is in progression [27, 28]. One such example of theranostic agent is manganese 
oxide nanoparticle carrying drugs and contrast agents [29] and silica nanoparticle 
with magnetic and fluorescent tags [30]. In the past few years, combination of 
metal nanoparticle or shells [31–33] with magnetic components has yielded dif-
ferent theranostic agents for biomedical applications which are widely used. Some 
examples of theranostic agents are given in Table 1.
3. Nano theranostics
Theranostic nanosystems comprise of platforms/nanocarriers that are used as 
imaging as well as therapeutic agents via a single entity. Nanotheranostic devices 
can be made by many types of inorganic and organic nanomaterials. Preclinical 
implementations make use of nanotheranostic system because they might provide 
a way or method of understanding many crucial aspects of drug delivery and how 
these systems can assist in knowing the power of personalized medicines.
4. Therapeutic agents
At present radiotherapy, surgery and chemotherapy are possible treatments for 
cancer patients. The purpose of the theranostic is to use these therapeutic strategies 
and reduce the risk associated with chemotherapy and radiotherapy and in addition 
to it avoid complications related to surgery and trauma. In addition, with the help 
Contrast 
agent





siRNA MRI plus RNA 
delivery
— — [15]






















CNTs DNA plasmid, DOX, 
PTX
Diagnosis, 






QDs DOX, MTX Imaging, therapy 
and sensing
— — [26]
Abbreviations: siRNA: short interfering ribonucleic acid, CNTs: carbon nanotubes, QDs: quantum dots, DOX: 
Doxorubicin, HPPH: 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-alpha, MTX: Methotrexate, PTX: 
Paclitaxel, MRI: Magnetic resonance imaging, CT: Computed topography.
Table 1. 
Different theranostic agents used for biomedical applications.
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of nanotechnology, theranostics may support the diversification of therapeutic 
approaches like PTT, PDT and immunotherapy. Here we report some of these 
therapeutic strategies often used in theranostics, like radiotherapy, chemotherapy, 
PDT, PTT and immunotherapy.
5. Chemotherapy for management of cancer
Anticancer drugs have proven beneficial in improving survival rate of cancer 
patients [34]. There are huge numbers of clinical anti-cancer drugs which are 
broadly applied to theranostics. On the basis of structure and resource of chemo-
therapy drugs, cancer therapeutic agents can be classified into six types: alkylating 
agent, antitumor antibiotic, phytogenic anticarcinogen, antimetabolites, hormone 
and miscellaneous anti-cancer drugs. Thermo DOX for liver cancer, Doxil for 
ovarian cancer therapy and Myocet for metastatic breast cancer are few cancer 
nanomedicines that have been approved by the FDA. Theranostic systems also make 
use of prodrugs like platinum (IV) prodrug to reduce the toxicity of drug and by 
increasing the active hits to the cells of tumors site. Due to their broad availability 
these prodrugs are very popular option. The UV light is transformed from NIR light 
by UCNP which activates the prodrugs to highly toxic platinum (II) complexes 
that enters the cell by endocytosis after grafted onto up converting nanoparticles 
(UCNP) [35]. In order to attain best therapeutic efficacy of drug delivery systems a 
high payload is essential. In theranostics, in order to maintain the original size and 
solubility in aqueous media a carrier with large pore volume and surface area are 
given preferences so that more therapeutic agent can be carried [36]. For example, 
Sorafenib with a loading ration of 28.2% can be loaded on porous silica nanopar-
ticles and may release the therapeutic agent in sustained fashion [37]. GO, Ws2 and 
MoS2 are some of the popular 2-D nanomaterials that have a very high drug payload 
as they can bear chemotherapeutics on both sides of sheet. Some of the example of 
high drug payload include 118% for 7-ethyl-10-hydroxycamptothecin (SN38) and 
approx 239% for DOX were observed on MoS2 [38], DOX (approximately 400%) 
on GO [39] was also significant. Cancer cells show multidrug resistance (MDR) 
often when they are treated by single drug which can be overcome by employing 
efficient strategies of theranostics. By combining P-glycoprotein (P-gp) reversing 
agent with anticancer drug the hurdle of MDR can be resolved [40]. The func-
tion of P-gp reversing agent is to avoid the pumping of chemotherapeutic drugs 
out of cancer cells due to over expression of P-gp. One way to overcome MDR is 
by covering the positive change that is present on anticancer drugs. DOX alone 
cannot produce significant cancer effect but when it is adsorbed on the surface of 
polymeric nanoparticle more chance are there that cancer cell may readily uptake 
it and accumulate within cancer cell and produce more cytotoxicity to cancer cell. 
Nanocarriers loaded with combination of anticancer drugs provide synergistic 
effect thereby improving overall management of cancer [41, 42].
6. Photothermal therapy for management of cancer
Microwave, light irradiation or magnetic field can potentiate the effect of 
thermal therapy which in turn employs hyperthermia to kill cancer cells. Among all 
the above mentioned therapies photothermal therapy has the maximum capacity 
to destroy cancer cell while causing least damage to nearby healthy cells. Localized 
hyperthermia under light irradiation at tumor site is generated by using NIR 
absorbing agent in photothermal therapy [43]. In MR region an ideal PTT agent 
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should show strong absorbance and must exhibit less fluorescence quantum yield 
thereby promoting efficient conversion of absorbed light energy into heat via non-
radiative transition rather than fluorescence emission.
Inorganic nanoparticles and organic dyes are extensively employed as PTT 
agents. Examples of organic dyes include Prussian blue, IR780, ICG, IR820, Cypate, 
IR825. These organic dyes have an added advantage of ease of loading on nanoplat-
forms and ideal NIR absorbance [44]. In order to improve the photostability and 
targeting ability of organic dyes they are being encapsulated into nanocarriers [45]. 
Carbocyanine dyes namely cypate and ICG were loaded into the polymeric micelle 
with loading rate of 50% and 20% for cypate and ICG respectively. Upon compar-
ing loaded theranostic polymeric micelle with carbocyanine dye alone showed 
marked cellular uptake and longer retention time at the site of tumor. Remarkable 
PTT results were observed along with increased photothermal effect and photo-
stability of organic dyes when nanomaterials like graphene derivatives absorbing 
strongly in the NIR regions were employed [46]. In NIR and PTT imaging tech-
niques both cypate and ICG can be used as theranostic agents.
Photothermal conversion efficiency will decrease in presence of high fluores-
cence quantum yield and fluorescence imaging is disturbed in case of low quantum 
yield hence there is not much surety in theranostic application of organic dyes. 
Apart from the organic dyes, a wide range of inorganic nanoparticles have been 
fabricated for theranostic applications. Inorganic nanoparticles exhibit strong 
photothermal conversion efficiency and NIR absorption for PTT. It encompasses 
customized gold nanostructure like nanoshell, nanocages, nanorods and nano-
tubes. On comparing the gold nanorods alone against gold nanorods coated with Pt 
nanodots, the latter showed significant better photothermal effect than the former 
[47]. And the better results were due to the presence of Pt shell in the endosomes 
which not only prevented the original sharp LSPR band of gold nanorods from 
shifting and dampening but also prevented the aggregation of gold nanorods. 
Carbon nanotubes [48], carbon dots [49], GO are some of the other nanomaterials 
that can used for PTT. GO for in-vivo PTT was used for the first time by Liu group. 
Further they reduced the GO to rGO which had 7 times more NIR absorption than 
GO hence increasing the PTT effect [50]. PTT for now might only be used for 
treating skin cancer and not for internal cancer because of limiting light penetra-
tion depth but its noteworthy therapeutics capacities with minimum possible side 
effect cannot be ignored. Further study is required to get deeper insight about how 
phototoxicity is caused by PTT.
Apart from PTT, hyperthermia induced magnetically is also one of the non-
invasive procedures to treat cancer [51]. Dielectric constant and microwave 
frequency between malignant tissue and normal tissue in breast can be employed 
for the detection and treatment of breast cancer. Dielectric contrast is used for 
scattering of an illuminating microwave signal and the incident microwave pro-
duces hyperthermia thereby treating malignant tissues [52].
7. Photodynamic therapy for management of cancer
Photosensitizers (PSs) used in PDT plays a vital role in the treatment of cancer 
and possess enormous potential. Cytotoxic reactive oxygen species or free radicals 
are generated when the molecular oxygen surrounding the diseased cell reacts with 
the absorbed light that is being transferred by PSs under laser irradiation which 
finally causes cell apoptosis and damage to cancerous cells [53]. No side effects are 




PDT requires low light density to cause damage to cancer cell unlike the PTT 
which requires high density laser light to generate hyperthermia that can cause 
damage to cancer cells [54]. PDT encompasses noteworthy advantages like very 
less invasiveness, on repeating the therapy is show no cumulative toxicity, very less 
damage to immune and hemopoietic system thereby improving the overall health 
and contributing to quality life for the patient. An ideal PS must have following 
properties like triplet state formation of high quantum yield and a good amount 
of triplet lifetime so that interaction with ground state oxygen is possible thereby 
generating sufficient ROS. However many PSs does not have good tumor selectiv-
ity, good amount of photosensitivity and absorption maxima above 700 nm [55]. A 
distinctive NIR absorption at 700 nm was observed by the help of extra axial mob 
linkers in monosubstituted phthalocyanine [56] that produced 20 nm red shift of 
characteristic Q band. PEG functionalized iron oxide nanocluster surface when 
loaded with Ce6 the absorption peak of chlorine e6 (Ce6) showed red shift from 
650 nm to 704 nm [57]. The energy transferred from UCNPs to PSs are able to excite 
the combination of PSs and UCNP’s, therefore inhibiting the growth of tumor by 
generation of cytotoxic singlet oxygen [58].
8. Radiation therapy for management of cancer
Radiation therapy has become an integral part to treat many sarcomas. The 
mechanism of action of radiation therapy is that the radiation damages strings of 
DNA in the nucleus of cells which stops the cell multiplication. Apart from afore-
mentioned functions of radiation therapy, it also produces reactive oxygen therapy 
(ROS) which indirectly damages the tumor cell and also damages the DNA of 
mitochondria and other organelle of cell. In case of surgical resection, the survival 
could be prolonged by employing radiation therapy. However due to frequent and 
repeated high dose of X-ray irradiation that causes systemic side effects and resis-
tance to radiation had been noticed in cancerous cells.
Metal nanoparticles in strong association with strong capacities of photoelectric 
absorbance are used as radiation dose enhancing agents. For example research 
shows that radio sensitization is being mediated by Gold NP due to greater energy 
deposition and absorption in surrounding tissue from photoelectrons. Radiotherapy 
with prolonged circulation time in blood has been demonstrated by Auger elec-
trons and characteristic X-rays [59] and polyethylene glycosylation modified gold 
nanoparticle (N GNPs). Radiotherapy can relieve the symptoms and prolong the 
lives of terminal cancer patients. However radiotherapy is not an easy task and 
may cause loss of organ functions also as it may also induce many complications. 
Moreover, it cannot completely remove cancer cells. In coming future we may see 
highly accurate and precise exposure of tumor site to high radiation by the applica-
tion of radiation wave knife for much better clinical results.
9. Immunotherapy for management of cancer
After radiotherapy, surgery or chemotherapy it has been observed that a small 
number of cancer cells may still remain alive and in addition to it the overall treat-
ment quality is also decreased due to drug resistance. Immunotherapy has great 
potential to treat cancer as it acts on the immune system rather than on the tumor 
itself. Immunotherapy is considered as a unique and promising strategy for cancer 
therapy [60] and the main advantages include its specific promotion on immune 
cells only aiming on target cells or target tissues. So far, the related investigations 
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have been gradually transformed from laboratory research to clinical practice. For 
clinical treatment the use of immunotherapeutic drugs such as immune checkpoint 
inhibitors and T cells have been approved by FDA and have great potential for 
cancer treatment. Improved immunotherapeutic nanomaterials loaded with anti-
gens, immune adjuvants and nucleic acids have been demonstrated to be helpful. 
The nanoplatforms may affect and alter immune cell actions and response non-
specifically. They may easily damage the cancer cells and achieve tumor targeting 
with pathogens factors. For e.g. repetitive and homogenous antigens conjugated 
with gold nanoparticles are able to trigger immune response in an in-vitro setting 
even without the use of adjuvant. Recently a combination of IR phthalocyanine dye 
IR700 with monoclonal antibodies had been fabricated and this novel technique 
is known as Photoimmunotherapy [61]. Least side effect and significantly fast cell 
necrosis rate is observed when antibodies bind to target tumor cells during the PIT 
and is activated by NIR light irradiation. Hence for monitoring and treating cancer 
in a highly selective manner PIT is a good theranostic approach.
10. Multimodal therapy for management of cancer
Conventional cancer therapies often do not succeed to eradicate tumor 
completely. In order to recover anticancer efficacy, the arrangement of two or 
more therapeutic modalities such as chemo photodynamic, photothermal pho-
todynamic, chemo photo thermal synergistic formulations have been explored. 
Thermomotherapeutic characteristics in association with theranostic methods 
result in development of anticancer drug that possess synergistic therapeutic effect 
[62]. Chemotherapy could be improved by the use of photothermal effect which 
aids the intracellular translocation of anti-cancer drugs [63]. Risk of overtreatment 
could be minimized along with the reduction in dose of therapeutic agent with 
less laser exposure time. All these can be attained by combination of PDT/PTT. 
Synergistic effect of PTT/PDT have been seen when GO was loaded with methylene 
blue [64]. In this system, lesser dose of nano GO was applied, as compared to the 
particular PTT treatment of nano GO. In addition, the PTT and PDT combina-
tional treatment could be spoil both superficial and deep regions of the tumor, 
and thus overcome the drawbacks of single treatments [65]. To further progress 
cancer therapy efficacy, numerous types of theranostic platforms were developed 
to combine chemotherapy, PTT and PDT simultaneously [66]. Treating cancer 
with combinational therapy has become an essential trend in cancer therapeutics. 
Compared to single modality therapy, the combined therapy can reduce the dosage 
of the drugs and thus decrease the side effects in treatment. More prominently, the 
combined therapy has the potential to decrease multidrug resistance of tumor cells, 
thus improving the therapeutic efficacy. The combined therapy may bring a novel 
opportunity to the next invention of cancer treatment [67].
11. Imaging-guided therapy for management of cancer
The theranostic nanoparticles have an ever increasing consideration for image 
guided therapy in current years because these nanoparticles can follow the phar-
macokinetic process, guide the treatment and monitor therapeutic process and 
outcome. They could be employed to imagine and quantify the performance of 
drug delivery systems for numerous special purposes such as biodistribution and 
pharmacokinetics of nanocarriers, metabolic response and drug release process of 
the nanocarriers. Koukourakis group and Harrington group engaged Technetium 
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and Indium labeled PEGylated liposomes respectively to monitor drug targeting to 
the sarcomas and breast cancer sites [69]. In the clinical practice, surgical resection 
is a regular and inevitable procedure for cancer therapy. Theranostics gives a pos-
sibility in intraoperative imaging to guide the operation process. During the surgery, 
Imaging 
method
Imaging agent Therapeutic agent Function
Optical 
Imaging
Cy5.5 Paclitaxel Real time tracking of NP 
location
FITC-coumarin pair Doxorubicin Drug release monitoring
Dicyanomethylene-4H-
pyran
Camptothecin Drug release monitoring
Cy7, 111In Cyclophosphamide, 
etoposide
Real time imaging of apoptosis
Cy5.5-BHQ pair Doxorubicin Real time imaging of apoptosis
Ce6 Ce6 Real time tracking of NP 
location & PDT




Cisplatin prodrug Imaging of NP location
UCNP (NaYF4:Er) TPGSd Dual imaging (optical, CT) & 
reducing multidrug resistance




Gd Doxorubicin Real time monitoring of drug 
delivery
SPION SPION Detection & hyperthermia 
treatment of tumor
SPION Doxorubicin Tumor detection & 
chemotherapy
SPION/FITC siRNA MR imaging & gene therapy
CT 
imaging
GNP Doxorubicin CT imaging of cancer & 
chemotherapy




64Cu Doxorubicin Quantitative biodistribution 
analysis & Chemotherapy
64Cu siRNA Quantitative determination of 




Perfluoropentane Docetaxel Triggered drug release & 
chemotherapy
CaCO3 Doxorubicin Tumor imaging & triggered 
drug release
Perfluorooctyl bromide Camptothecin Chemotherapy & ablation 
therapy




Theranostic technologies for cancer treatment [68].
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physicians could congregate the diagnostic information for precise imaging as well 
as visualized therapy. In theranostic platform, DOTA-Gd act as a MRI contrast agent 
for preoperative finding and surgical planning; the Raman molecules visualized the 
excellent margin of tumor, allowing precise resection for the duration of operation 
process. The multimodal NP could recognize tumor edge for precise resection of 
tumor. This approach could be planned for simple intraoperative navigation and 
real-time imaging [70]. Theranostic technologies commonly utilized for cancer 
treatment are given in Table 2.
12. Conclusion
Theranostic approach to management of cancer offers numerous advantages. 
They are designed to monitor cancer treatment in real time. A wide variety of 
theranostic nanoplatforms that are based on diverse nanostructures like magnetic 
nanoparticles, carbon nanotubes, gold nanomaterials, polymeric nanoparticles, 
or silica nanoparticles showed great potential as cancer theranostics. Nano thera-
peutic platforms have been successful in integrating image guidance with targeted 
approach to treat cancer.
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